SCHEMBL10076866

SCHEMBL10076866

CCC(=O)CCC(N)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIK1 P39086 3/20 0.60
SLC1A3 P43003 3/20 0.60
SLC1A2 P43004 3/20 0.60
SLC1A1 P43005 3/20 0.60
GRIK2 Q13002 2/20 0.60
GSR P00390 2/20 0.60
GRIA4 P48058 2/20 0.60
GRIK3 Q13003 2/20 0.60
GRIK5 Q16478 2/20 0.60
GRM8 O00222 1/20 0.60
GRM6 O15303 1/20 0.60
GRIN2D O15399 1/20 0.60
GRIN3B O60391 1/20 0.60
CYP1A2 P05177 1/20 0.60
GRM5 P41594 1/20 0.60
GRIA1 P42261 1/20 0.60
GRIA2 P42262 1/20 0.60
GRIA3 P42263 1/20 0.60
GRIN1 Q05586 1/20 0.60
GRIN2A Q12879 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15342759 1.00 GRIK1 (0.60) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL16577954 0.90 GRIK1 (0.54) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL22164119 0.85 ALOX15 (0.76) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL27872833 0.85 ALOX15 (0.76) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL3486168 0.85 GSR (0.55) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL7362969 0.84 GSR (0.53) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL7791775 0.84 GSR (0.53) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL12998158 0.82 TDP1 (0.39) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
Glutamic Acid SCHEMBL564069 0.82 GRM8 (0.82) GRIK1SLC1A3SLC1A2SLC1A1GRIK2
SCHEMBL19455873 0.82 ALOX15 (0.41) GRIK1SLC1A3SLC1A2SLC1A1GRIK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11807664-B2 Method for producing cyclic organic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-11-07 US disclosed
WO-2020159448-A1 MOLECULAR RENAL PROBES FOR DETECTING ACUTE KIDNEY INJURY NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2020-08-06 WO disclosed
US-9593079-B2 Stabilized multi-functional antioxidant compounds and methods of use XPD HOLDINGS, LLC (US) 2017-03-14 US disclosed
US-20170015990-A1 HYBRID POLYKETIDE SYNTHASES ENERGY, UNITED STATES DEPARTMENT OF 2017-01-19 US disclosed
US-20160185718-A1 Stabilized Multi-Functional Antioxidant Compounds and Methods of Use XPD HOLDINGS, LLC 2016-06-30 US disclosed
US-20160058728-A1 CANCER STARVATION THERAPY SERBIG PHARMACEUTICALS CORP. (PR) 2016-03-03 US disclosed
WO-2012148550-A1 PRODRUGS OF THERAPEUTIC COMPOUNDS MYREXIS, INC. (US) 2012-11-01 WO disclosed
EP-2468744-A2 Inhibitors of serine proteases, particularly HCV NS3-NS4A protease VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-06-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160058728-A1 CANCER STARVATION THERAPY TUFM, TFAM, GFM1 GRIK1 1613/4885SLC1A3 904/4885SLC1A2 1282/4885
US-20160185718-A1 Stabilized Multi-Functional Antioxidant Compounds and Methods of Use SOD1, GPX4, SOD3 GRIK1 2928/4885SLC1A3 4340/4885SLC1A2 4464/4885
US-11807664-B2 Method for producing cyclic organic compound SCTR, CTRC, DCXR GRIK1 4686/4885SLC1A3 4799/4885SLC1A2 4848/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.